From the High Plains to the World:

Maurice Hilleman and the Montana Origins of Modern Vaccine Science

Maurice Ralph Hilleman was born on August 30, 1919, on a farm near Miles City, Montana, at the precise moment in history when the most lethal influenza pandemic ever recorded was killing tens of millions of people worldwide. Few would have predicted, looking at the unpromising circumstances of that birth, that the child arriving on those windswept eastern Montana plains would grow up to become the most prolific vaccine developer in the history of medicine. His twin sister died at birth, and his mother passed away just days afterward. Raised by an aunt and uncle on the family farm along the banks of the Tongue and Yellowstone Rivers, Hilleman knew hard physical labor from an early age, reportedly sent to sell strawberries at a local market as young as age four. The hardships of that upbringing did not diminish him; they formed him. Over the course of a sixty-year career, he developed more than forty vaccines, an unparalleled record of productivity, eight of which are among the fourteen vaccines routinely recommended in American childhood vaccine schedules.

A Boyhood Forged in Adversity

The landscape of southeastern Montana in the early twentieth century was not known for producing world-historical scientists. The region was cattle and wheat country, defined by distance, drought, and the relentless demands of subsistence agriculture. Growing up during the Great Depression on a farm in the southeastern plains of Montana, Hilleman needed to be economical and tenacious to help his family survive, a foundation he later drew upon to maintain focus throughout his career. The family’s Lutheran faith and the cultural memory of the frontier shaped the household, and records indicate that Hilleman’s great-uncle had served as an Indian scout in the United States cavalry in the years following the Battle of Little Bighorn.

The young Hilleman demonstrated an early intellectual curiosity that sat uneasily within the framework of rural Montana’s expectations. In the eighth grade, he discovered Charles Darwin and was caught reading On the Origin of Species in church. His scientific interests had found a direction, though the path forward was far from clear. Despite graduating from Miles City High School in 1937, Hilleman was not initially planning to attend college. He had been planning to accept a career-track position at a J.C. Penney store in Miles City when his older brother told him that Montana State College offered scholarships. That intervention proved to be one of the pivotal moments not only in Hilleman’s life, but in the history of public health.

Montana State and the Making of a Scientist

Hilleman was awarded a full scholarship to Montana State College, where he majored in chemistry and microbiology. His years in Bozeman were a period of intellectual transformation. During his freshman year he spent his weekends in the laboratory. He graduated first in his class in 1941. The institution left a permanent impression on the scientist he was becoming. In a 1999 issue of Immunological Reviews, Hilleman described Montana State as a “no-nonsense institution where professors taught,” an environment that suited his temperament and his fundamental belief that science existed to produce practical results.

After Montana State, Hilleman won a fellowship to the University of Chicago, where the academic culture was rigorous and demanding. Living on limited finances, he ate one meal a day, his 138-pound frame a testament to the austerity of those years. His doctoral research addressed a question with significant medical consequences: whether chlamydia was caused by a virus or a bacterium. Through his doctoral work, Hilleman determined that chlamydia was in fact caused by a bacterium, which meant it could be treated with antibiotics. This discovery, made at a time when many clinicians assumed otherwise, had immediate practical implications for treatment. He and one of his professors also taught the first course ever offered in virology at the University of Chicago.

The tension between academic and industrial science defined the conclusion of his graduate career. Hilleman told his professors at Chicago that he was going into industry, where he believed he would be best positioned not only for conducting research but also for ensuring and expediting clinical applications. His professors objected, insisting that he belonged in academia. Hilleman strongly disagreed, and the decision to pursue pharmaceutical science rather than academic tenure would allow him to develop, test, and deploy vaccines at a scale no university laboratory could have supported.

Walter Reed and the Science of Pandemic Preparedness

Upon completing his doctorate in 1944, Hilleman joined E.R. Squibb and Sons, where he worked on a vaccine against Japanese B encephalitis, a disease threatening American troops fighting in the Pacific theater of World War II. In 1948, he moved to the Walter Reed Army Institute of Research in Washington, D.C., where he was assigned to study respiratory illnesses of military significance and to devise a strategy for averting the next influenza pandemic. In what he described as a startling revelation, influenza A viruses showed gradual and progressive minor antigenic changes punctuated infrequently by major changes. Those patterns, now called drift and shift, became the basis of modern influenza vaccine strategies.

The distinction between antigenic drift and antigenic shift is fundamental to understanding why influenza vaccines must be reformulated annually and why certain influenza strains can trigger global pandemics. Drift refers to the small, incremental mutations that accumulate in a virus season over season. Shift refers to the sudden, dramatic genetic reassortment that produces a strain so novel that human immune systems carry no prior exposure to it. Hilleman observed that the influenza virus underwent changes: sometimes small, but other times dramatic. The small changes became known as antigenic drift, and the sudden major changes became known as antigenic shift. Antigenic shift can result in pandemics because almost no one in the world is immune to a significantly altered virus. This conceptual framework, now a cornerstone of influenza epidemiology, was Hilleman’s own synthesis.

The Pandemic He Stopped in Its Tracks

The fullest demonstration of Hilleman’s singular capabilities came in 1957. On April 17 of that year, he read a report in The New York Times describing a massive influenza outbreak in Hong Kong, noting that in long lines at clinics, women carried glassy-eyed children tied to their backs. To most readers it was a distant foreign crisis. To Hilleman, it was unmistakable: a pandemic was forming. He obtained a virus specimen from a Navy serviceman stationed in Japan and studied it. His analyses showed that the new influenza strain was distinctly different from type A strains previously isolated in the United States and Europe, and only a few elderly people who had survived the influenza pandemic of 1889 to 1890 showed any antibody response to it.

Hilleman moved quickly to alert the government, predicting that the virus would hit American shores in the first week of September, right when schools would reopen. He was declared crazy, as he later recalled, and the U.S. Public Health Service initially dismissed his warnings. Undeterred, Hilleman bypassed official channels and went directly to pharmaceutical manufacturers. He demanded that roosters that would otherwise have been culled be kept alive to fertilize enough eggs to produce the vaccine. Even though his work had not yet been reviewed by the main U.S. vaccine regulatory agency, the pharmaceutical companies agreed. Hilleman’s childhood experience raising chickens on a Montana farm had given him a practical understanding of agricultural production cycles that, in 1957, directly informed one of the most consequential public health decisions of the twentieth century.

Forty million doses of the vaccine had been created by the time the flu reached American shores in fall 1957. Without the vaccine, it was predicted that as many as one million Americans would have died; with it, between seventy thousand and one hundred sixteen thousand Americans died from the virus. Hilleman later reflected that it was the only time a pandemic had been averted through vaccination. He received the Distinguished Service Medal from the United States military for this achievement.

Decades of Innovation at Merck

At the end of 1957, Hilleman joined Merck and Company as director of a new department of virus and cell biology research. He would remain associated with Merck for the rest of his professional life. Under his leadership, by 1984 Merck had garnered thirty-seven product licenses, with an additional three vaccines ready for development. The breadth of his output during these decades was extraordinary.

In 1963, when his daughter Jeryl Lynn showed the classic symptoms of the mumps, Hilleman swabbed the back of her throat, brought the sample to the laboratory to culture, and by 1967 there was a licensed vaccine. The mumps strain he isolated from his daughter that night is still used in the mumps component of the MMR vaccine administered to children around the world today, known formally as the Jeryl Lynn strain. Hilleman was also the first person to combine viral vaccines when he created the MMR vaccine, allowing children to be protected against measles, mumps, and rubella with a single injection.

In 1969 Hilleman created a rubella vaccine and combined it with his mumps and measles vaccines, licensing the MMR shot in 1971. By 2015, physicians had administered more than five hundred million doses of the vaccine worldwide. Its impact on preventing congenital rubella syndrome alone, a condition that caused severe fetal malformations when pregnant women contracted rubella, represents an incalculable reduction in human suffering.

When Hilleman created the hepatitis B vaccine, he became the first person to develop a vaccine against a virus that causes liver cancer in humans. The process involved his team collecting blood from high-risk intravenous drug users in New York City, a dangerous project that involved handling material that often contained live virus. The FDA was reluctant to authorize human trials given the inherent risk of disease transmission, so members of Hilleman’s own staff served as initial test subjects. The vaccine was licensed in 1981. By 2003, one hundred fifty countries were using it, and the incidence of hepatitis B in young people in the United States had decreased by ninety-five percent. Hilleman considered this work to be his single greatest achievement. Liver transplant pioneer Thomas Starzl noted that controlling the hepatitis B virus ranked as one of the most outstanding contributions to human health of the twentieth century and that Hilleman had removed one of the most important obstacles to the field of organ transplantation.

His innovations extended beyond specific vaccines. He contributed to the development of vaccines using human diploid cells derived from the WI-38 cell line, which have since immunized hundreds of millions of people and form the cellular substrate for oral poliomyelitis, measles, rubella, varicella, mumps, rabies, adenovirus, and hepatitis A vaccines. He also identified simian virus SV40, a contaminating agent found in early polio vaccines produced between 1955 and 1963, and isolated adenoviruses, discovered while investigating a respiratory outbreak at Fort Leonard Wood, Missouri, in 1953.

A Legacy Larger Than Its Public Recognition

Despite a body of work that reshaped modern medicine, Hilleman remained largely unknown outside scientific circles throughout his lifetime. Few people in the general public ever encountered the name of the man who developed some forty vaccines. The question of why has several answers. Hilleman consistently declined to name any of his vaccines after himself, though the Jeryl Lynn mumps strain carries his daughter’s name. Stanley Plotkin, who co-developed the rubella vaccine with Hilleman, suggested that the lack of public recognition may reflect the fact that Hilleman worked for industry, which contrasts with the public perception of figures like Pasteur, Salk, and Sabin as scientists unconnected to commercial enterprise.

Hilleman’s personality also complicated his public profile. During more than sixty years in basic and applied research, he earned a reputation as an often harsh and impatient figure who engaged in direct conflict with industry and government bureaucracies. He defended his approach as essential for science to advance, arguing that politics rather than science too often determined which breakthroughs reached the marketplace. He expected total commitment from those who worked for him and had little patience for institutional inertia when lives were at stake. His standards were, by every account, applied first and most rigorously to himself.

The honors he received were substantial. He received the Albert Lasker Public Service Award in 1983, the National Medal of Science in 1988, and a World Health Organization lifetime achievement award in 1996. He was elected to the National Academy of Sciences in 1985 and the National Academy of Medicine in 1995. Merck rehired him immediately as a consultant upon his mandatory retirement at age sixty-five to keep him involved in vaccine research and development. Robert Gallo, co-discoverer of HIV, stated in 2005 that if he had to name a person who had done more for the benefit of human health with less recognition than anyone else, it would be Maurice Hilleman, whom he called the most successful vaccinologist in history.

Montana’s Claim on a Giant of Medicine

The state of Montana has not forgotten its most consequential scientific son. His name is spoken alongside Jonas Salk and Louis Pasteur as a pioneer who fundamentally changed human health. Montana State University has honored him through the Hilleman Scholars Program and the Maurice Hilleman Vaccine Symposium, an ongoing academic event that brings researchers in microbiology and immunology to Bozeman to continue the work he made possible. The Hilleman Scholars Program offers financial assistance and leadership development to first-generation and economically disadvantaged students, embodying the circumstances of Hilleman’s own path to higher education.

The connection between Hilleman’s Montana upbringing and his scientific career was not merely biographical. His farm experience with chicken husbandry gave him the practical knowledge that ensured the production of forty million influenza vaccine doses in 1957. His Depression-era resourcefulness trained him to find solutions within constraints that would have defeated a less determined scientist. His characteristic directness, which many found abrasive, had its roots in the plainspoken culture of the eastern Montana plains. Walter Strauss, a senior director of epidemiology research at Merck, observed that here was a man born on some windswept ranch in Montana, practically orphaned at birth, taken in by relatives, who but for his talent and drive might never have left Miles City at all.

Maurice Ralph Hilleman died on April 11, 2005, in Philadelphia, Pennsylvania, at the age of eighty-five, having volunteered his own lung cells for experimental cancer research near the end of his life. According to one estimate, his vaccines save nearly eight million lives each year. He left behind no vaccine bearing his name, no public statue in a prominent American city, and no household recognition commensurate with the scale of his achievement. What he left behind was something larger: a world in which measles, mumps, rubella, hepatitis A, hepatitis B, chickenpox, meningitis, and pneumonia no longer kill and maim children at the rates that once made them ubiquitous features of human childhood. The boy from Miles City did not merely pursue a scientific career. He changed the biological conditions of human life on a global scale, and he did it with the tenacity of a Montana farm hand who simply refused to accept that something could not be done.

Works Cited

Giles, Jim. “From Farm Boy to Vaccine King.” The Biologist, Royal Society of Biology, https://thebiologist.rsb.org.uk/biologist-features/from-farm-boy-to-vaccine-king. Accessed 21 March 2026.

Hilleman Film. “About Dr. Hilleman.” Medical History Pictures, Inc., https://hillemanfilm.com/dr-hilleman. Accessed 21 March 2026.

“History of Vaccines: Maurice Hilleman, PhD.” College of Physicians of Philadelphia, https://historyofvaccines.org/history/maurice-hilleman-phd/overview/. Accessed 21 March 2026.

“Maurice R. Hilleman.” The Lancet, vol. 365, no. 9472, 14 May 2005, pp. 1723-1724, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66536-1/fulltext. Accessed 21 March 2026.

“Maurice Ralph Hilleman (1919-2005).” Embryo Project Encyclopedia, Arizona State University, https://embryo.asu.edu/pages/maurice-ralph-hilleman-1919-2005. Accessed 21 March 2026.

Montana State University. “About Dr. Hilleman.” Hilleman Scholars Program, https://www.montana.edu/hillemanscholars/biography.html. Accessed 21 March 2026.

Montana State University. “Dr. Hilleman’s Legacy.” https://www.montana.edu/hilleman100/legacy.html. Accessed 21 March 2026.

Newman, Liz. “Maurice Hilleman.” BMJ: British Medical Journal, vol. 330, no. 7498, 2005, p. 1028. PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC557162/. Accessed 21 March 2026.

Offit, Paul A. Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. Smithsonian Books / Collins, 2007.

Petsko, Gregory A. “The Man Who Developed 40 Vaccines.” University of Chicago Magazine, https://mag.uchicago.edu/science-medicine/man-who-developed-40-vaccines. Accessed 21 March 2026.

Saplakoglu, Yasemin. “How America Brought the 1957 Influenza Pandemic to a Halt.” JSTOR Daily, https://daily.jstor.org/how-america-brought-the-1957-influenza-pandemic-to-a-halt/. Accessed 21 March 2026.

Simpson, J. Cavanaugh. “The Man Who Beat the 1957 Flu Pandemic.” Scientific American, 15 April 2020, https://www.scientificamerican.com/blog/observations/the-man-who-beat-the-1957-flu-pandemic/. Accessed 21 March 2026.

Tulchinsky, Theodore H. “Maurice Hilleman: Creator of Vaccines That Changed the World.” Case Studies in Public Health, 2018, pp. 443-470. PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC7150172/. Accessed 21 March 2026.

“Life-Saving Vaccine Scientist Maurice Hilleman.” Montana Press, 16 Sept. 2024, https://www.montanapress.net/post/famous-and-not-forgotten-life-saving-vaccine-scientist-maurice-hilleman. Accessed 21 March 2026.​​​​​​​​​​​​​​​​